Patents Examined by Claire M. Kaufman
  • Patent number: 6858578
    Abstract: Chimeric proteins useful in transporting a selected substance present in extracellular fluids, such as blood or lymph, into cells; quantitative assays for the selected substance using chimeric proteins; DNA encoding the chimeric proteins; plasmids which contain DNA encoding the chimeric proteins; mammalian cells, modified to contain DNA encoding the chimeric proteins, which express and, optionally, secrete the chimeric proteins; a method of producing the chimeric proteins; a method of isolating the chimeric proteins; a method of using the chimeric proteins to assay the selected substance; and a method of reducing extracellular levels of the selected substance through administration of the chimeric protein, which results in transport of the selected substance into cells.
    Type: Grant
    Filed: January 3, 2001
    Date of Patent: February 22, 2005
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Michael W. Heartlein, Jeffrey F. Lemontt, Michael F. Concino
  • Patent number: 6846914
    Abstract: The present invention provides for an isolated nucleic acid molecule encoding a member of the TIE ligand family. The present invention also provides for an isolated nucleic acid molecule encoding TIE ligand-3 or TIE ligand-4. In addition, the invention provides for a receptorbody which specifically binds TIE ligand-3 or TIE ligand-4. The invention also provides an antibody which specifically binds TIE ligand-3 or TIE ligand-4. The invention further provides for an antagonist of TIE. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: January 25, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David M. Valenzuela, Pamela F. Jones, George D. Yancopoulos
  • Patent number: 6843990
    Abstract: The invention provides monoclonal antibodies against decoy receptor 3 (DcR3), hybridomas producing said antibodies, kits containing said monoclonal antibodies and uses of the hybridomas, antibodies and kits for the detection of DcR3-associated diseases, as well as for the treatment and/or prevention of DcR3-associated diseases.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: January 18, 2005
    Assignee: Anawrahta Biotech Co.
    Inventors: Mai Shen-Chih, Liu Shih-Jen
  • Patent number: 6841382
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: January 11, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • Patent number: 6841367
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: January 11, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • Patent number: 6825168
    Abstract: The invention is drawn to anti-thrombin proteins from the salivary glands of the species, Simulium. Methods for recombinant production of the protein as well as biomedical uses are provided.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: November 30, 2004
    Assignee: Auburn University
    Inventors: Mary S. Cupp, Eddie W. Cupp
  • Patent number: 6797513
    Abstract: The present invention relates to nucleic acid molecules encoding mCLK2, mCLK3, and mCLK4 polypeptides, nucleic acid molecules-encoding portions of their amino acid sequences, nucleic acid vectors harboring such nucleic acid molecules, cells containing such nucleic acid vectors, purified polypeptides encoded by such nucleic acid molecules, and antibodies to such polypeptides. Also included are assays that contain at least one CLK protein kinase related molecule. Diagnosis and treatment of an abnormal condition related to RNA splicing or cell proliferation in an organism by using a CLK protein kinase related molecule or compound are disclosed. A method of using a CLK protein kinase related molecule or compound as a contraceptive to reproduction in male organisms is also disclosed.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: September 28, 2004
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Axel Ullrich, Oliver Nayler
  • Patent number: 6780836
    Abstract: Relaxin is useful for promoting angiogenesis and the treatment of infections or ischemic wounds where the injury results from lack of oxygen due to poor circulation.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: August 24, 2004
    Assignee: BAS Medical, Inc.
    Inventor: Elaine Unemori
  • Patent number: 6774219
    Abstract: An isolated and purified DNA molecule encoding Candida albicans protein with integrin-like motifs, the protein itself, antibodies thereto, and methods of use, are provided.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: August 10, 2004
    Assignee: Regents of the University of Minnesota
    Inventors: Margaret K. Hostetter, Cheryl A. Gale, Kathleen Kendrick
  • Patent number: 6764679
    Abstract: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: July 20, 2004
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, David Botstein, Kelly H. Dodge, Audrey Goddard, Austin L. Gurney, Kyung Jin Kim, David A. Lawrence, Robert Pitti, Margaret A. Roy, Daniel B. Tumas, William I. Wood
  • Patent number: 6743625
    Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: June 1, 2004
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
  • Patent number: 6696290
    Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: February 24, 2004
    Assignee: Genentech, Inc.
    Inventors: Vincent Daniel Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
  • Patent number: 6664075
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by tissue patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: December 16, 2003
    Assignees: President and Fellows of Harvard College, Imperial Cancer Research Technology Ltd.
    Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin, David A. Bumcrot, Elisa Marti-Gorostiza
  • Patent number: 6660497
    Abstract: A cDNA encoding a 200 kD receptor, BT-R2, from the pink boll worm, Pectinophora gossypiella, that binds specifically to a Bacillus thuringiensis toxin has been cloned, sequenced and characterized. The minimum toxin binding fragment has been identified. The BT-R2 cDNA permits the analysis of receptors in pink boll worm and other insects that affect crop growth and development, as well as, design assays for the cytotoxicity and binding affinity of potential pesticides. The clone and other methods described herein, permit the manipulation of natural and/or introduced homologous receptors and, thus, to specifically destroy organisms, tissues and/or cells of the target host.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: December 9, 2003
    Assignee: The Board of Regents, The University of Texas System
    Inventors: Lee A. Bulla, Jr., Mehmet Candas
  • Patent number: 6653084
    Abstract: The isolation, cloning and characterization of a human gene related to but distinct from the EGF receptor gene has been described. Nucleotide sequence of the gene and amino acid sequence of the polypeptide encoded by the gene have been determined. The use of the nucleic acid probes and antibodies having specific binding affinity with said polypeptide for diagnostic and therapeutic purposes has also been described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 25, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: C. Richter King, Matthias H. Kraus, Stuart A. Aaronson
  • Patent number: 6632618
    Abstract: Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptors particularly OP-1-binding cell surface receptors ALK-2, ALK-3, and ALK-6; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods for identifying novel morphogen receptors and their encoding DNAS; (4) methods and compositions for identifying compounds capable of modulating endogenous morphogen receptor levels; and (5) methods and compositions for identifying morphogen receptor binding analogs useful in the design of morphogen agonists and antagonists for therapeutic, diagnostic and experimental uses.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: October 14, 2003
    Assignees: Curtis, Inc., Ludwig Institute for Cancer Research
    Inventors: Peter ten Dijke, Carl-Henrik Heldin, Kohei Miyazono, Kuber T. Sampath
  • Patent number: 6630310
    Abstract: A preparation containing a receptor for underivatized, aqueous soluble &bgr;(1-3)-glucan is disclosed, along with characterization of the receptor for underivatized, aqueous soluble &bgr;(1-3)-glucan. Also described are assays for identifying agents which alter the effect of underivatized, aqueous soluble &bgr;(1-3)-glucan on activation of signal transduction pathways and agents identified thereby, as well as assays for assessing the specificity of carbohydrate:glycolipid interactions.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: October 7, 2003
    Assignee: Biopolymer Engineering Pharmaceutical, Inc.
    Inventors: Eric Wakshull, William M. Mackin, Janet Zimmerman
  • Patent number: 6613565
    Abstract: Primitive hematopoietic stem cells are closely associated with discrete in vivo microenvironments. These “niches” are thought to provide the molecular signals that mediate stem cell differentiation and self renewal. We have dissected the fetal liver microenvironment into distinct cellular components by establishing an extensive panel of stromal cell lines. One particular cell line maintains repopulating stem cells for prolonged in vitro culture periods. A subtraction cloning strategy has yielded a cDNA which encodes a cell surface glycoprotein with a restricted pattern of expression among stromal cell lines. This molecule, previously identified as dlk/Pref-1, contains EGF-like repeats which are related to those in the Notch/Delta/Serrate family of proteins. We have investigated the potential role of this molecule in hematopoietic stem/progenitor cell regulation.
    Type: Grant
    Filed: December 8, 1998
    Date of Patent: September 2, 2003
    Assignees: ImClone Systems Incorporated, Trustees of Princeton University
    Inventors: Larry Witte, Bronislaw Pytowski, Kateri A. Moore, Ihor R. Lemischka
  • Patent number: 6610656
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: August 26, 2003
    Assignees: President and Fellows of Harvard College, Imperial Cancer Research Technology, Ltd.
    Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin
  • Patent number: 6607913
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: August 19, 2003
    Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin